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ABSTRACT
Insomnia is a prevalent sleep disorder. We examined chronic insomnia in terms of subjective and objective measures,
according to self-reported duration of disorder. 443 patients were included from a sleep clinic diagnosed with chronic
insomnia (ICSD3 criteria). Patients were retrospectively evaluated in terms of medical interview, sleep questionnaires,
a standard polysomnography study, and subdivided in subgroups according to disorder duration. We compared
patient’s results to a control group. Insomnia and control groups were significantly different in terms of TST, SE,
SOL, N1 sleep, REM sleep, REM latency and number of REM episodes (p<0.05). For the group of ≤1 year of
insomnia disorder all PSG parameters were statistically different from controls, except N2% and N3%, REM latency,
and number of REM episodes. In the groups of 2 to 4 years, 10 to 19 years, and ≥ 20 years of insomnia we found the
same differences except for REM sleep. On the contrary, in a subgroup analysis of 5 to 9 years of insomnia disorder
duration, no differences to control group were found in TST, N1 or REM sleep to control group, adjusted for age.
The polysomnographic sleep profile of chronic insomnia patients is different over time. It sketches an initial attempt
of compensation in initial years of insomnia, which seems to disappear in long time chronic insomnia patients, as we
usually see in others neurodegenerative disorders. Future studies are needed to clarify the natural history of chronic
insomnia disorder and its behaviour as a neurodegenerative disorder.
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INTRODUCTION
Insomnia is a common complaint defined by difficulties in
falling asleep, maintaining sleep, and/or early morning
awakening, coupled with daytime consequences such as fatigue,
attention deficits, and mood instability [1]. As a transient
phenomenon, insomnia is a commonplace and frequently remits
spontaneously. For chronic insomnia, the symptoms must occur
at least three times per week and persist over a period of at least
three months [1]. As a disorder, it frequently accompanies other
disorders, including other sleep disorders and many medical,
neurological and psychiatric disorders [2]; it can precede the
comorbid condition, persist despite an effective treatment of the
comorbid condition, or aggravate the symptoms of the comorbid
condition [2]. Results of longitudinal studies show that nearly
70% of individuals with insomnia at baseline continue to report
insomnia one year later, and 50% still have insomnia up to three
years later [3-5]. Chronic insomnia raises the risks for depression
[6,7], hypertension [8], and, possibly, mortality [9,10] in older
adults.
The natural history as well as the prognosis of untreated
insomnia is not well documented.
Some studies have approached the neurobiological basis of
insomnia by looking at structural differences between persons
with insomnia and good sleeper controls with no sleep
problems. Patients with primary insomnia demonstrated
significantly reduced hippocampal volumes bilaterally compared
to the good sleepers [11]. Riemann et al. tentatively concluded
that insomnia may either result from, or contribute to, changes
in brain structure [11]. Koo et al. showed again that sleep quality
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hippocampus and putamen [12]. In addition, two studies have
used diffusion tensor imaging (DTI) to evaluate differences in
white matter tracts in persons with insomnia compared to
matched controls [13,14]. By taking a whole-brain network
perspective, Jespersen et al succeeded at integrating previous
inconsistent findings, and revealed that reduced structural
connectivity of the left insula and the connections between
frontal and subcortical regions are central neurobiological
features of insomnia disorder.
These results although not always reproducible, started to
demonstrate that insomnia disorder patients have structural and
functional brain differences compared to good sleepers and may
raise the possibility that insomnia is more than a psychological
or even psychiatric disorder, seeming to be a neurological
disorder.
Clinically and in many research studies, insomnia is primarily
diagnosed by the measurement of subjective symptoms and not
by the determination of sleep parameters through
polysomnography [15]. Polysomnographic research on insomnia
revealed a remarkable discrepancy between the subjective
experience of insomnia and a rather undisrupted sleep at
polysomnography in many insomniacs [16]. However, currently
polysomnography is the only objective and quantitative measure
for insomnia. Although, no standardised quantitative
definitions for insomnia exist, several criteria are suggested:
average reported sleep latency of more than 30 minutes,
wakefulness after sleep onset of more than 30 minutes, sleep
efficiency of less than 85% or total sleep time lower than 6.5h in
adults [17].
To our knowledge, there is no clinical data about changes in
polysomnography related to duration of the insomnia disorder.
Therefore, we extensively evaluated a clinical population of
chronic insomnia patients from a Sleep Medicine Centre,
including complaints, comorbidities, socio-demographic data
and sleep questionnaires, together with Polysomnography (PSG)
type 1. The objectives of this study were: 1) to evaluate our
chronic insomnia patient data and to compare it with a control
group; 2) to evaluate chronic insomnia PSG patterns according
to self-reported duration of disorder.
METHODS
Participants
The population consisted of a retrospective analysis of 443
consecutive patients from a sleep clinic diagnosed with chronic
insomnia, according to the ICSD3 criteria [1], determined by a
board-certified sleep physician during a clinical interview
between January 2014 and May 2018. Participant sleep
difficulties had to be longer than 3 months, not related to any
medical or another sleep disorder condition, or medication
intake. In opposition, the control group did not meet ICSD3
criteria for insomnia, sleep satisfaction was preserved, had no
reports on difficulty in initiating sleep, maintaining sleep, or
early morning awakening and showed PSG night study without
any change (Total Sleep Time (TST) >6.5h, Sleep Onset Latency
(SOL) <30 minutes, Sleep Efficiency (SE) >85%, Index Apnea
Hipopnea (IAH) <5/h, Periodic Limb Movements (PLMs)
<15/h).
Exclusion criteria for all participants: (a) current presence of a
medical or neurological disorder that could significantly disrupt
sleep; (b) alcohol or drug abuse according to diagnostic criteria
of substance-related disorders of DSM-V [18]; (c) evidence of
another sleep disorder (e.g., sleep apnea, periodic limb
movements during sleep, restless legs syndrome).
Procedures
All individuals had a clinical interview performed by a
neurologist specialized in sleep medicine, followed by
polysomnography type I measurements. In the clinical
evaluation the detailed clinical history of the patient was
obtained. Data like socio-demographic parameters (e.g. age,
gender, marital status); toxic consumptions like tobacco, alcohol
abuse, illicit drugs as well as licit drugs (prescribed and non-
prescribed by a physician) like anti-depressive and hypnotic
drugs, as well as self-prescribed melatonin use was recorded. All
reported co-morbidities were assessed - depression, anxiety,
psychiatric disorders, neurologic disorders and medical disorders
(according to the diagnoses criteria of DSM V [18] and ICD-10
[19]. This is a retrospective study (clinical anonymized database
analysis) as so, informed consent was not required. In the
absence of an institutional review board, as an ethical
committee, we followed the good clinical practices worldwide
recommended including the principals ’  outlined by the
Declaration of Helsinki.
Measures
Polysomnography: Overnight polysomnography was performed
with one of the following PSG systems: Alice 5 Respironics;
Nicolet System – Viasys Healthcare; Embla N7000; Domino
Somnoscreen Plus - Somnomedics. The recorded parameters
included in all of them: electroencephalography (F3-M2, F4-M1,
C3-M2, C4-M1, O1-M2, O2-M1); left and right
electrooculogram; submental electromyogram; bilateral tibial
electromyogram; electrocardiogram; oronasal airflow with 3-
pronged thermistors; nasal pressure with a pressure transducer;
rib cage and abdominal wall motion via respiratory impedance
plethysmography. Arterial oxygen saturation with pulse
waveform was also recorded, as well as digital video and audio.
The sleep period was scored from “lights off” to “lights on,”
with lights off scheduled as close as possible with participant’s
normal sleep schedule. Objective sleep measures evaluated were:
sleep onset latency (SOL), total sleep time (TST), sleep efficiency
(SE in %) scores were derived by dividing total TST by TIB and
multiplying by 100 to achieve a percentage, proportion (%) of
sleep stages (1,2,3 and REM) in relation to TST, REM latency,
number of REMs.
Questionnaires: Pittsburgh Sleep Quality Index - PSQI is a self-
report 18 questions on subjective sleep quality over the last four
weeks. The 18 items of the PSQI form seven component score
ranging from 0 to 3 (sleep quality, sleep latency, sleep duration,
sleep efficiency, sleep disturbances, sleep medication, daytime
dysfunction) the sum generate a total score. Higher scores
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represent worse sleep quality. The cut-off values established for
“bad” sleep quality is a total score 5 [20].
Insomnia Severity Index (ISI) is a valid and reliable self-report
instrument measuring perceived insomnia severity. The severity
of sleep disturbances, satisfaction relative to sleep, degree of
impairment of daytime functioning caused by sleep, noticeability
of impairment attributed to the sleep problem, and the degree
of distress and concern related to the sleep problem are reported
throughout the seven items on a 5-point (0 to 4) Likert scale.
The total score ranges from 0 to 28 (higher scores reveal more
severe insomnia symptoms) [21].
Epworth Sleepiness Scale (ESS) is a self-reported questionnaire
composed by 8 items, which assesses the level of sleepiness in
daily situations, rated on a 4 point Likert scale, ranging between
“0 - no probability of falling asleep” and “3 - high probability of
falling asleep”. The total score is obtained by adding all items,
ranging between 0 and 24. Results at or above 10 indicate
abnormal or pathological daytime sleepiness and results at or
above 17 indicate severe sleepiness [22].
Misperception: A total sleep time misperception (time in
minutes) was calculated using objective (PSG recording) and
subjective (oral information) data of night PSG study obtained
after the morning awakening.
Statistical analysis
Absolute frequencies and proportions were used to summarize
categorical variables. Continuous variables were described by
mean values and standard deviations for normal distributions
and by median whenever normality criteria were not met.
Differences between groups on sociodemographic, psychological,
and sleep characteristics were statistically assessed using the
Student t-test or Mann-Witney test for continuous variables,
according to data distribution, and the Chi-square test for
categorical variables. Statistical assumptions of parametric tests
were verified. In case of violation, nonparametric options were
preferred. Anova followed by post-hoc Bonferoni was also
performed related to sleep characteristics. Significance levels




The sample comprised 443 insomnia patients (295 women,
16-83 years old, mean=44.8 years, SD=14.2), 51 controls (32
women, 19-74 years old, mean 43.3 years, SD=12). Statistical
analysis showed that groups were similar according to age and
gender (p>0.05). Additionally, none of the subjects had an
apnea-hypopnea index ≥ 5, ruling out sleep apnea. Similarly,
none of the subjects met AASM criteria [23] for an objective
diagnosis of periodic limb movements disorder, restless legs
syndrome or an underlying parasomnia.
Questionnaires
Subjective sleep parameters related to ISI were significantly
different between groups (insomnia 18.2 ± 4.6 vs. controls 12.4
± 2.8, p=0.01). PSQI also showed differences between both
groups (insomnia patients 11.59 ± 3.72 vs. control group 6.6 ±
1.84, p<0.001). In the insomnia group, only 1.1% (5 patients)
had a PSQI <5 meaning a good sleep quality. However, not
significantly differences in Epworth Sleep Scale (insomnia 9.6 ±
5.1 vs. controls 10.2 ± 5, p=0.614) were found.
Objective sleep parameters
Insomnia and control groups were significantly different in TST
(insomnia 348.4 ± 70.4 min vs. controls 409.0 ± 52.2 min,
p<0.001), SE (insomnia 73.8 ± 13.3% vs. controls 89.2 ± 5.6%,
p<0.001), SOL (insomnia 29.3 ± 29.9min vs. controls 11.2 ± 8.3
min, p<0.001), N1% (insomnia 9.3 ± 5.1% vs. controls 5.7 ±
2.7%, p <0.001), REM% (insomnia 16.9 ± 9.1% vs. controls
20.8 ± 6.0%, p=0.001), REM latency (insomnia 138.0 ± 76.4min
vs. controls 102.8 ± 64.0 min, p<0.001) and number of REM
episodes (insomnia 3.1 ± 1.2 vs. controls 3.9 ± 1.1, p < 0.001)
(Table 1).
For those who reported the exact time of onset of insomnia, we
looked for differences in PSG data by separating patients in five
subgroups taking into account insomnia disorder duration: ≤ 1
year, 2 to 4 years, 5 to 9 years, 10 to 19 years and ≥ 20 years, in
comparison with the control group. For the group of ≤ 1 year of
insomnia disorder all PSG parameters were statistically different
from controls, except N2% and N3% (both with p=1.0), REM
latency (p=0.862), and number of REM episodes (p=0.238). In
the groups of 2 to 4 years, 10 to 19 years, and ≥ 20 years of
insomnia we found the same differences except for REM sleep
(%, latency and number of REM episodes). However, in the
group of 5 to 9 years of insomnia, no differences were found in
TST (p=0.23), N1% (p=0.587), N2% (p=1), N3% (p=1.0) and
REM sleep% (p=1.0), REM latency (p=1.0) and number of REM
episodes (p=0.295) (Table 2 and Figure 1). Linear regression
with the subgroups taking into account insomnia disorder
duration did not find any interaction with age.
Sleep was underestimated in all chronic insomnia groups but
also in the control group, however for all insomnia groups the
misperception error was more than one hour (Table 2).
Table 1: Group differences based on sociodemographic variables, questionnaires and objective sleep parameters.
 Chronic Insomnia Control group p-value
N 443 51  
Sex, Female - % (N) 66.6 (295) 62.7 (32)  
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Age (yrs) 44.8 ±14.2 43.3 ± 12 0.505
ESS 9.6 ± 5.1 10.2±5 0.614
ISS 18.2±4.6 12.4±2.8 0.01
PSQI 11.6 ± 3.7 6.6 ± 1.8 <0.001
PSG data
TST*, min 348.4 ± 70.4 409.0 ± 52.2 <0.001
Sleep Onset Latency, min 29.3 ± 29.9 11.2 ± 8.3 <0.001
Sleep efficiency, % 73.8 ± 13.3 89.2 ± 5.6 <0.001
N1 % TST 9.3 ± 5.1 5.7 ± 2.7 <0.001
N2 % TST 53.3 ± 10.9 52.6 ± 8.4 0.53
N3% TST 21.9 ± 35.0 21.3 ± 7.7 0.51
REM % TST 16.9 ± 9.1 20.8 ± 6.0 0.001
REM Latency, min 138.0 ± 76.4 102.8 ± 64.0 <0.001
Number of REM episodes 3.1 ± 1.2 3.9 ± 1.1 <0.001
Average Heart Rate, bpm 63.7 ± 8.6 65.2 ± 8.1 0.356
Snore% 8.4 ± 15.7 11.8 ± 16.2 0.01
Apnea/hypopnea index (/h) 1.6 ± 1.9 1.8 ± 1.7 0.15
O2 mean saturation, % 95.6 ± 1.5 94.9 ± 2.2 0.06
Periodic Limb Movements i (/h) 2.4 ± 3.7 1.8 ± 3.3 0.23
Note: Mean values ± SD (range) are shown; ESS=Epworth Sleepiness Scale; ISS=Insomnia Severity Index; PSQI=Pittsburgh Sleep Quality Index;
TTS=Total Sleep Time; SOL=Sleep Onset Latency; N1=N1 sleep; N2=N2 sleep; N3=N3 sleep; REM=REM sleep
Table 2: Group differences compared to control group based on polysomnographic parameters by separating patients in five subgroups taking into
account insomnia disorder duration.
Controls ≤1 yr 2-4 yrs 5-9 yrs 10-19 yrs ≥ 20 yrs
N 51 21 23 24 26 18
TTS, min 409.0 ± 52.2 320.1 ± 66*** 352.3 ± 59.3** 368.0 ± 60.9 360.4 ± 62.1* 331.0 ± 98.3***
SOL, min 11.2 ± 8.3 29.8 ± 22.1** 25.1 ± 18.8* 26.2 ± 22.5* 28.2 ± 17.6* 33.8 ± 27.1**
SE, % 89.2 ± 5.6 68.6 ± 14.1*** 76.0 ± 10.3*** 77.4 ± 11.4** 75 ± 11.5*** 70.0 ± 18.2***
N1, %TST 5.7 ± 2.7 9.1 ± 3.8** 9.1 ± 5.4** 7.7 ±2.9 9.4 ± 4.0** 9.7 ± 4.6**
N2, % TST 52.6 ± 8.4 50.6 ± 8.2 51.5 ± 11.6 54.6 ± 8.7 53.3 ± 7.7 56.3 ± 13.5
N3, % TST 21.3 ± 7.7 25.0 ± 9.1 22.6 ± 12.5 18.7 ± 10.5 19.4 ± 7.5 15.8 ± 10.4
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REM, % TST 20.8 ± 6.0 15.1 ± 7.6** 16.8 ± 6.9 19.0 ± 5.5 17.8 ± 5.5 18.0 ± 6.5
REM Latency, min 102.8 ± 64.0 138.2 ± 79.2 126.5 ± 71.2 130.1 ± 57.2 119.4 ± 62.4 122.1 ± 85.4
Number of REMs 3.9 ± 1.1 3.1 ± 1.3 3.0 ± 1.1 3.2 ± 1.3 3.6 ± 1.1 3.3 ± 1.1
Sleep Misperception, min 27.4 ± 93.2 77.7 ± 104.1 72.5 ± 118.2 92.7 ± 109.6 77.7 ± 112.6 83.2 ± 113.3
Note: Mean values ± SD (range) are shown. TTS=Total Sleep Time; SOL=Sleep Onset Latency; N1=N1 sleep; N2=N2 sleep; N3=N3 sleep;
REM=REM sleep. *Indicates a significant difference to control group at P < 0.05; ** Indicates a significant difference to control group at P<0.01; ***
Indicates a significant difference to control group at P<0.001. Adjusted by age.
Figure 1: Group differences compare to control group based on polysomnographic parameters by separating patients in five subgroups taking into
account insomnia disorder duration. Mean values ± SD (range) are shown. TTS=Total Sleep Time; SOL=Sleep Onset Latency; N=N1 sleep; N2=N2
sleep; N3=N3 sleep; REM=REM sleep. * Indicates a significant difference to control group at P<0.05; ** Indicates a significant difference to control
group at P<0.01; *** Indicates a significant difference to control group at P<0.001. Adjusted by age.
DISCUSSION
The primary aim of this study was to determine whether
differences existed in terms of sleep, both subjectively and
objectively, between chronic insomnia patients and a control
group. Subsequently we looked for differences in chronic
insomnia groups considering the duration of the insomnia
disorder.
The differences between chronic insomnia patients and controls
were not surprising. TST, SE were lower and SOL was longer in
insomnia patients as expected and in line with previous studies
[17,24]. We also found differences in N1 and REM sleep (%,
latency and number of episodes of REM) between insomnia
patients and the control group. The increased N1 % is
consistent with the hyperarousal model of insomnia [25,26]; the
reduction of REM sleep in insomnia was also found in previous
studies. It is thought to play a key role in alteration of the
emotional system [27].
Furthermore, when we looked to the consequences of untreated
chronic insomnia over time, in the first year of insomnia the
differences found in the objective sleep measures in comparison
to the control group were also in TST, SE, SOL, N1 and REM
sleep (%). However, no differences related to REM latency or
number of REMs were found. The same was found for the
groups of 2 to 4 years, 10 to 19 years and ≥ 20 years of insomnia,
with exception of REM sleep (%, latency and number of REM
episodes). As mentioned before, previous studies already showed
that primary insomnia patients spend 2% less time in REM
sleep [24]. This is correlated with the alteration of emotional
processes that usually follows insomnia [4].
There was however a consistent approximation found between
insomnia patients within 5 to 10 years duration and the control
group related to objective sleep measures. In initial years of
chronic insomnia, TST and N1 sleep PSG parameters assumes
an inverted “U” shape and looks like a compensation response
over time, which after 10 years tends to disappear; this
approximation to the control group is achieved by increasing the
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TST and decreasing N1. In chronic insomnia there is not only a
sleep-wake regulation problem with an increase in awake state:
brief periods of awakening, increased number of microarousals
or with periods of wakefulness during night; but also a
disturbance of the switch between sleep and wakefulness – as
both NREM and REM microstructure seems to suggest [28]. In
our results, chronic insomnia seems to have an initial evolution
period (after the first year reaching its maximum between 5 and
9 years) with an attempt to alter the arousal system and the sleep
continuity, increasing the total sleep time and decreasing N1
sleep. This mechanism behaves like a compensation response
operating in the early phase of chronic insomnia to allow a
restoration of the normal sleep-wake regulation.
Several molecules involved in sleep-wake regulation are
produced by specific brain structures with widespread projection
throughout the brain [29]. If sleep regulatory molecules
(primarily wake-promoting/sleep-suppressing or sleep-
promoting/wake-suppressing substances) affect neurons in the
regions they are produce, it will affect the neural circuitry of
sleep in which those neurons take part [30]. Yet, the sleep/wake
system stops working properly and patients may have insomnia.
In the field of speculation, we may hypothesize that even if a
compensation mechanism may occur by recruiting other
neurons and other circuits, overtime, the compensation could
end rather due to the spread of the areas affected and the
compensation stopped being effective. The long-term
complications due to chronic insomnia could be related to the
role of the impaired sleep-wake process and the consequently
poor sleep.
Neurodegenerative diseases have two general characteristics: the
pathology associated with the disease only affects particular
neurons (‘selective neuronal vulnerability’) and the pathology
worsens with time and impacts more regions in a stereotypical
and predictable fashion [31]. Thus, we may say that chronic
insomnia behaves as a neurodegenerative disorder as presenting
selective neuronal vulnerability [30] and, as our results showed,
worsening with time
An initial compensatory mechanism is found in other
degenerative disorders, in which the natural response to the
insult cannot resolve the problem, and may even give rise to
further damage, but individuals, due to compensation
mechanisms, may persist asymptomatic in initial phases of the
disease (for example, Parkinson disease [32] or chronic kidney
disease [33]) or exhibit minor manifestations for a long time (for
example, Alzheimer disease (AD)) [34].
A neurodegenerative process in chronic insomnia, growing over
several years, also may explain some differences found in MRI
studies mentioned in the introduction. Winkelman et al. did
not replicate the results of Riemann et al., that showed changes
in MRI in chronic insomnia patients and the reason may be
related to sample composition [11,35]. Winkelman had a sample
with 20 patients which reported a continuous history of
insomnia for at least six months, 19 for at least one year and 12
for at least five years [35]. In Riemann study, eight patients were
included and had suffered from insomnia for a mean duration
11.6 ± 8.9 years. The changes in MRI studies may only happen
with a longer disease duration. Koo et al. [12], which showed
again that insomnia disorder is closely related to atrophic
changes in hippocampus and putamen, had a sample of 27
insomnia patients with an average time since onset of insomnia
of 8.4 ± 9.1 years. The last two samples, with a duration of
insomnia enough to lose initial compensatory mechanism that
we now showed. Also, in terms of MRI changes, chronic
insomnia disorder may behave like AD, where the accumulation
of amyloid plaques and neurofibrillary tangles is contemplated
to induce neural and synaptic loss that finally leads to cortical
atrophy [36]. As in AD, which has atrophic changes that occur
first in the hippocampus, are not specific enough and can only
been seen years after the first memory symptoms, insomnia
disorder may have MRI images changes only several years after
initial insomnia complaints.
Furthermore, cognitive behaviour therapy for insomnia (CBT-I)
seems to be the most efficacious treatment for chronic
insomnia. CBT-I is effective across a variety of populations,
including those with medical and psychologic comorbidities.
Unexpectedly, McCrae et al, presented novel evidence suggesting
that CBT-I may slow or reverse cortical gray matter atrophy in
patients with fibromyalgia and insomnia [37], showing that
psychologic strategies may change circuits and even structural
damage.
Sleep misperception was present in chronic insomniacs. We
found that sleep misperception error increased in the first 10
years of insomnia symptom. At the same time % of REM sleep
also increases. The previous and current results support the
suggestion that REM sleep might be related with the
mechanisms of sleep misperception [16].
LIMITATIONS OF THE STUDY
This is a retrospective study, which may be associated with
potential methodological shortcomings (e.g., recall bias).
However, with such a window of time (more than 20 years) a
prospective study has complex design and with a follow up
period that will lead to an important number of drop offs. Still,
these new results highlight the need of such a study in the
future. It will also be interesting to look to sleep microstructure,
namely microarousals, and spectral EEG components, namely,
spindles and alpha activity intrusion. As strengths we highlight
the insomnia sample size, which is an unfrequented number of
chronic insomnia patients with PSG data.
CONCLUSION
The focus of the study was to examine the consequences of the
presence of untreated chronic insomnia over time in PSG. So, if
insomnia is in fact a primarily remitting condition what should
happen to the smaller group of patients with a persistent
disorder? As the Spielman’s model proposed insomnia can start
with an initial precipitant event and may resolve over time. In
our point of view, for those that did not remit, an initial attempt
to compensate will include an increase on TST, decrease of
N1% and increase of REM%. However, this compensation
works only for a few years and when lost, the persistent disorder
may worse over time, increasing the risk for future onset of
psychopathology or even cognitive impairment. A similar
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mechanism has been described in the development of dementia,
in which an initial compensation occurs due to a cognitive
reserve hiding the brain damage already existing. In that sense,
chronic insomnia behaves as a neurodegenerative disease in
terms of progressive degeneration of the function of the central
nervous system, namely the sleep/wake system, with an initial
compensation response and ulterior deterioration, including
structural MRI changes. Further studies are however needed to
prove this hypothesis.
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